arrow
I

Inder S. Anand

veterans affairs medical center and university of minnesota
H指数:112
被引数:5.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF

沙库巴曲缬沙坦及采用EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS)评估的生活质量,在HFrEF和HFmrEF/HFpEF患者中的研究。

2025-09-010
OA
Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

与肥胖度相关的体质测量指标及在轻度射血分数降低或保留的心力衰竭中的临床结局

JACC
IF0
2025-08-270
PRE
Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

利钠肽、体重指数及轻度射血分数降低或保留的心力衰竭患者的临床结局

JACC
IF0
2025-08-270
PRE
Growth differentiation factor-15 and the effect of dapagliflozin in heart failure: insights from the DAPA-HF trial

生长分化因子-15及达格列净在心力衰竭中的效果:DAPA-HF试验的启示

2025-08-150
OAAI
Obesity and Risk of Kidney Outcomes in Heart Failure With Preserved Ejection Fraction

肥胖与射血分数保留的心力衰竭中肾脏结局的风险

2025-06-090
PRE
Clinical Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction and With Reduced Ejection Fraction According to the Prognostic Nutritional Index: Findings From PARADIGM-HF and PARAGON-HF

根据预后营养指数评估射血分数保留和射血分数降低的心力衰竭患者的临床特征和结局: 来自paradig-hf和PARAGON-HF的发现

2025-01-070
OAAI
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Preserved Trial

比较研究者报告与中心裁定心力衰竭结局的EMPEROR-Preserved试验

2025-01-011
PRE
Pulse Pressure in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Pooled Participant-Level Analysis of 4 Large-Scale Trials

心力衰竭伴轻度降低或保留射血分数的脉压:4项大规模试验的参与者水平合并分析

2024-11-120
PRE
Sex, Adiposity-Related Anthropometrics, and Clinical Outcomes in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Participant Level Pooled Analysis of Randomized Trials

性别、脂肪相关性人体测量指标及轻度射血分数降低或保留的心力衰竭患者的临床结局:一项随机试验的参与者水平合并分析

2024-11-120
PRE
Age, Adiposity-Related Anthropometrics, and Clinical Outcomes in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A ParticipantLevel Pooled Analysis of Randomized Trials

年龄、与肥胖相关的体质测量指标以及轻度射血分数降低或保留的心力衰竭的临床结局:一项随机试验的受试者水平合并分析

2024-11-120
PRE
Systolic Blood Pressure in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Pooled Participant-Level Analysis of 4 Large-Scale Trials

心力衰竭伴轻度降低或保留射血分数时的收缩压:一项基于4项大规模试验的合并受试者水平分析

2024-11-120
PRE
Natriuretic peptides, kidney function and clinical outcomes in heart failure with mildly reduced or preserved ejection fraction: pooled data from the I-PRESERVE, TOPCAT, PARAGON and DELIVER trials

射血分数轻度降低或保留的心力衰竭患者的利钠肽、肾功能和临床结局: 来自i-preserve、TOPCAT、PARAGON和DELIVER试验的汇总数据

2024-10-280
PRE
Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction

射血分数轻度降低和保留的心力衰竭患者 β 受体阻滞剂的使用和预后

2024-08-310
PRE
Clinical characteristics and outcomes of patients aged 80 years and over with heart failure: Need for better treatment
2024-08-211
OA
Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT-CHF (European) study with the ASIAN-HF registry

左心室射血分数改善与持续降低的心力衰竭: BIOSTAT-CHF (欧洲) 研究与亚洲-HF注册的比较

2024-08-094
OA
Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF
2024-07-230
PRE